Vogenx removes funding conditions from trial timelines in latest S-1/A

Filed August 10, 2026 · Compared to S-1/A Jul 29, 2026 · ~1 min read

Key Changes

• high

  Vogenx removed 'subject to additional funding' language from its EMERGE and gastroparesis trial timelines, now stating it expects to begin recruiting in 2026 and initiate the gastroparesis study in 2027.

  Business view on EDGAR →
• medium

  The company added a quantitative PBH prevalence estimate of over 160,000 symptomatic patients in the U.S., plus additional hypo-unaware and mild-to-moderate patient groups.

  Business view on EDGAR →
• medium

  Vogenx updated its description of FDA orphan designation history for PBH, now stating the FDA 'recognized' PBH as a subset of HH and 'previously granted' orphan designation, while noting the FDA's current view that PBH may not be rare.

  Business view on EDGAR →